GRS

TRANSLATE

MENU menu

Close close menu

GRS News

Launchpad: life and health sciences, Northern Ireland

7/11/2023

Are you a MedTech manufacturer looking to create new devices that can improve the lives and health of people? If so, you might be interested in a new funding opportunity from Innovate UK.

Opportunity status: Open

Funders: Innovate UK

Funding type: Grant

Total fund: £2,000,000

Publication date: 27 October 2023

Opening date: 30 October 2023 9:30am UK time

Closing date: 13 December 2023 11:00am UK time

 

Innovate UK is the UK’s innovation agency, which supports businesses to develop and realise the potential of new ideas. They have recently launched a competition for business-led projects that grow activities in the life and health sciences innovation cluster in Northern Ireland.

 

The life and health sciences innovation cluster is a network of organisations that collaborate to develop and deliver innovative solutions for health and wellbeing challenges. The cluster includes companies, universities, research institutes, hospitals, and public sector bodies.

 

The aim of this competition is to support outstanding innovation projects led by businesses. Your business must be active or growing work activities in the life and health sciences innovation cluster in Northern Ireland.

Your project must focus on innovation in life and health sciences.

Your project must lead to increased investment into research and innovation. It must contribute to growing business activities and economic impact in the cluster.

 

Your proposal must explain how your team and project will contribute to equality, diversity and inclusivity (EDI) in the cluster.

 

Portfolio approach

Innovate UK reserve the right to fund a variety of projects across different durations, locations, themes and across one or more of the following:

  • biomarker discovery and validation
  • medical technology devices
  • translation or validation of precision medicine approaches


Your project can focus on one or more of the following:

Diagnostics, therapeutics and biomarkers

  • multi-omics
  • medical imaging
  • liquid biopsy
  • biomarker or genetic testing
  • diagnostic or therapeutic development

 

Data, digital and medical devices

  • point-of-care testing
  • wearable or ambient sensors
  • clinical trials decision support
  • augmented reality
  • digital health

 

Innovations in healthcare service delivery

  • health service productivity
  • integrated care platforms
  • remote rehabilitation

 

Your project can also consider the following enabling areas:

  • artificial intelligence, machine learning, quantum
  • advanced therapies, novel formulation or delivery
  • regulation or ethics
  • supporting innovation in skills development

 

These lists are not exhaustive. Where you can show your proposal fits within the scope of this Launchpad competition, you can focus on other themes.

 

The total funding available for this competition is up to £2 million. The maximum grant per project is £250,000. The projects must start by 1 April 2024 and end by 31 March 2026. They can last between 12 and 24 months.

The deadline for applications 13 December 2023 11:00am UK time. You can find more details and apply on the Innovation Funding Service.

 

While you apply for the grant, our expert team at Global Regulatory Services [GRS UK] can support you with end-to-end Regulatory and Quality Compliance support. Right from grant writing to executing the Regulatory tasks, GRS will help you bring your innovation to Market Success.

 

GRS specialises in Regulatory Affairs of medical devices and in vitro diagnostics. Our team of experts can guide you through the complex and changing regulatory landscape of the EU and UK.

 

GRS can help you with:

  • Regulatory strategy: Develop a clear and effective plan to achieve regulatory approval for your device in the EU and UK.
  • Technical documentation: Preparing and maintaining the required technical documentation to demonstrate the safety, performance, and quality of your device.
  • Clinical evaluation: Conducting a systematic assessment of the clinical evidence to support the intended use and claims of your device.
  • Post-market surveillance: Implementing a proactive process to monitor the performance of your device after it is placed on the market and take corrective actions if needed.
  • Quality management system: Establishing and maintaining a quality management system that meets the requirements of ISO 13485 and other relevant standards.

Our Sister company, Med-Di-Dia, can also be your authorised representative in the EU. This means they can represent you before the competent authorities and ensure your compliance with the applicable regulations.

If you want to learn more about how GRS can help you bring your innovative device to the EU and UK markets, contact us via email – grs@globalregulatoryservices.com or fill out this contact page -  Contact GRS (globalregulatoryservices.com)

 

 

Back...